Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986253 + Cabiralizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986253 | HuMax-IL8|MDX 018|MDX-018|BMS986253|BMS- 86253 | BMS-986253 (HuMax-IL8) is a monoclonal antibody that targets interleukin-8 (CXCL8, IL8) to prevent activation of the receptors, CXCR1 and CXCR2, in effort to prevent immune escape and tumor progression (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3091-3091). | ||
Cabiralizumab | FPA008|FPA-008|FPA 008|BMS-986227 | CSF1R Antibody 5 | Cabiralizumab (FPA008) is a monoclonal antibody that targets the ligand-binding domain of CSF1R (PMID: 26051995). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|